ARA-290 for Inflammation
Research, mechanism, dosing, and effectiveness of ARA-290 for inflammation.
Quick Answer
ARA-290 has anti-inflammatory properties in multiple tissues.
Evidence Level
Phase II/III Trials
Typical Dose
Clinical trial dosing
Results Timeline
Anti-inflammatory effects in research
FDA Status
Research Only
How ARA-290 Works for Inflammation
Activates innate repair receptor without stimulating red blood cell production.
About Inflammation
Reduction of chronic inflammation and inflammatory responses in the body.
Research Evidence
Phase II/III clinical trials for diabetic neuropathy show improvement in corneal nerve fiber density and small fiber function. Orphan Drug Designation granted in both US and EU for sarcoidosis treatment. Studies demonstrate efficacy in small fiber neuropathy, neuropathic pain, and sarcoidosis-related symptoms. Being developed by Araim Pharmaceuticals.
Dosing for Inflammation
Recommended Dose
Clinical trial dosing
Frequency
Once daily
Administration
Subcutaneous injection
Duration
28-day courses in trials
Note: Cibinetide. Clinical trial doses. Used for neuropathy and sarcoidosis. Non-erythropoietic EPO derivative.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Generally well-tolerated in trials
- •Injection site reactions
- •No erythropoietic effects (no blood thickening)
- •Not FDA approved
Frequently Asked Questions
Does ARA-290 help with inflammation?
ARA-290 has anti-inflammatory properties in multiple tissues.
How does ARA-290 work for inflammation?
Activates innate repair receptor without stimulating red blood cell production....
What dose of ARA-290 should I use for inflammation?
Clinical trial dosing
How long until I see results?
Anti-inflammatory effects in research
Other Peptides for Inflammation
These peptides are also researched for inflammation.
GB-115
Clinical TrialsA dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia with completed Phase 3 trials for anxiety. Users report significant improvements in focus, attention, and ADHD-like symptoms.
Selank
Clinical TrialsA synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.
Semax
Clinical TrialsA synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Approved in Russia for stroke and cognitive enhancement. Known for nootropic and neuroprotective effects.
Cerebrolysin
Clinical TrialsA mixture of low-molecular-weight neuropeptides derived from pig brain. Approved in many countries for stroke, traumatic brain injury, and dementia.
Educational Information Only
This information about ARA-290 for inflammation is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.